<DOC>
	<DOC>NCT02650817</DOC>
	<brief_summary>The purpose of this study is to visualize and quantify ER-binding sites during treatment with RAD1901</brief_summary>
	<brief_title>A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Key 1. Patients with histologicallyproven, ERpositive, human epidermal growth factor receptor 2 (HER2)negative, locally advanced, inoperative, and/or mBC 2. Tumor progression after â‰¥ 6 months of at least 1 line of hormonal systemic treatment (SERM, SERD, or aromatase inhibitor) in the metastatic setting 3. Measurable disease according to RECIST criteria v1.1 or clinically evaluable disease 4. Greater than or equal to 18 years of age 5. Patients must be postmenopausal 6. Life expectancy &gt;3 months Key 1. Prior anticancer treatment or investigational drug therapy within the following windows: 1. Tamoxifen or fulvestrant therapy &lt; 42 days before 1st 18FESPET scan 2. Any other anticancer endocrine therapy &lt; 14 days before 1st dose of study drug 3. Any chemotherapy &lt; 28 days before 1st dose of study drug 4. Any investigational drug therapy &lt; 28 days or 3 halflives (whichever is longer) prior to the 1st dose of study drug 2. Patients with symptomatic central nervous system (brain) metastases 3. Patients with known endometrial disorders, including evidence of endometrial hyperplasia, dysfunctional uterine bleeding, or cysts</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>